Solventum SOLV Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Solventum in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Solventum’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solventum's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solventum's cash & equivalents?
- Solventum (SOLV) reported cash & equivalents of $561M in Q1 2026.
- How has Solventum's cash & equivalents changed year-over-year?
- Solventum's cash & equivalents increased by 5.1% year-over-year, from $534M to $561M.
- What is the long-term trend for Solventum's cash & equivalents?
- Over 3 years (2022 to 2025), Solventum's cash & equivalents has grown at a 143.3% compound annual growth rate (CAGR), from $61M to $878M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company has on hand.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for investment, while a decrease may indicate heavy spending or cash flow constraints.
- How does cash & equivalents compare across companies?
- Peers in the healthcare sector typically maintain cash levels proportional to their working capital requirements and M&A strategy.